Your browser doesn't support javascript.
Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic.
Bueno, Fernanda; Abelleira, Erika; von Stecher, Florencia; de Lima, Andrea Paes; Pitoia, Fabián.
  • Bueno F; Division of Endocrinology, University of Buenos Aires, Buenos Aires, Argentina.
  • Abelleira E; Division of Endocrinology, University of Buenos Aires, Buenos Aires, Argentina.
  • von Stecher F; Department of Pathology, University of Buenos Aires, Buenos Aires, Argentina.
  • de Lima AP; Department of Pathology, University of Buenos Aires, Buenos Aires, Argentina.
  • Pitoia F; Division of Endocrinology, University of Buenos Aires, Buenos Aires, Argentina, fpitoia@intramed.net.
Arch Endocrinol Metab ; 65(2): 242-247, 2021 Nov 01.
Article in English | MEDLINE | ID: covidwho-1080888
ABSTRACT
Anaplastic thyroid carcinoma is the rarest tumor of the thyroid gland, representing less than 2% of clinically recognized thyroid cancers. Typically, it has an extremely rapid onset, fatal outcomes in most cases, and a median overall survival of 3 to 10 months despite aggressive multidisciplinary management. The presence of targetable mutations in anaplastic thyroid carcinoma patients is an opportunity for treatment when conventional therapeutics approaches are not effective, a frequent situation in the majority of patients. We present our experience in the management of a patient with unresectable anaplastic thyroid cancer who had a remarkable and rapid response to treatment with dabrafenib and trametinib during the COVID-19 pandemic. After four weeks of dabrafenib 150 mg twice daily plus trametinib 2 mg daily, he showed a dramatic reduction of the cervical mass around 90%. Nearly eight weeks under treatment with dabrafenib plus trametinib, the patient remains with minimal locoregional disease without distant metastases.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Thyroid Neoplasms / Thyroid Carcinoma, Anaplastic / COVID-19 Type of study: Case report / Prognostic study Limits: Humans / Male Language: English Journal: Arch Endocrinol Metab Year: 2021 Document Type: Article Affiliation country: 2359-3997000000325

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Thyroid Neoplasms / Thyroid Carcinoma, Anaplastic / COVID-19 Type of study: Case report / Prognostic study Limits: Humans / Male Language: English Journal: Arch Endocrinol Metab Year: 2021 Document Type: Article Affiliation country: 2359-3997000000325